Rehan Khan Explores Clopidogrel
Rehan Khan, Hospital Pharmacist and Manager Auctus Hospital, shared on LinkedIn:
”Day 2/365 – Medicine of the Day: CLOPIDOGREL
One-Sentence Definition
Clopidogrel is an antiplatelet drug used to prevent blood clot formation in patients with cardiovascular and cerebrovascular diseases.
Pharmacological Overview
Drug class: Antiplatelet agent (P2Y₁₂ receptor inhibitor)
Drug type: Prodrug
Primary role: Prevention of arterial thrombosis
Therapeutic Uses
- Acute Coronary Syndrome (ACS)
- Post–myocardial infarction (MI)
- Stroke and TIA prevention
- After coronary stent placement
- Alternative in aspirin intolerance
Mechanism of Action (MOA)
- Inhibits ADP (P2Y₁₂) receptors on platelets
- Prevents activation of GPIIb/IIIa complex
- Lowers Platelet aggregation
- Effect lasts for platelet lifespan (7–10 days)
Common Dose
- Maintenance dose: 75 mg once daily
- Loading dose (ACS/PCI): 300–600 mg stat
Key Adverse Effects
Bleeding (most common)
Gastrointestinal upset
Rare: Thrombotic thrombocytopenic purpura (TTP)
Clinical Pearl
Clopidogrel is a prodrug—its efficacy depends on liver enzyme activation (CYP2C19).
HISTORY OF CLOPIDOGREL
1980s: Development of thienopyridine antiplatelets
1997: Clopidogrel approved for clinical use
CAPRIE trial: Showed superiority over aspirin in reducing ischemic events
Modern era: Backbone of dual antiplatelet therapy (DAPT) with aspirin
Why Clopidogrel Matters
- Essential in cardiology and interventional practice
- Life-saving in stent patients
- WHO essential cardiovascular medicine
Widely used globally in ACS protocols”
Stay updated with Hemostasis Today.
-
May 23, 2026, 16:55Rahul Bhargava: Ensure Equal Recognition of Clinical Haematologists in Blood Cancer Clinical Trials
-
May 23, 2026, 16:44Brian O Mahony: World Haemophilia Day Receives Global WHO Recognition
-
May 23, 2026, 16:44Yusuf Hameed: Gene Therapy Could Reduce Lifetime Treatment Burden in Hemophilia A
-
May 23, 2026, 16:43Chokri Ben Lamine: Pacritinib Is a Key JAK Inhibitor for Cytopenic Myelofibrosis
-
May 23, 2026, 16:42Bartosz Hudzik: Bleeding Risk Alone Should Not Determine Treatment Intensity
-
May 23, 2026, 16:42Shimels Tessema: Celebrating the WHA Resolution on Hemophilia and Other Bleeding Disorders
-
May 23, 2026, 16:38José Octavio Alva Bucio: Securing the Future of Plasma and Blood-Derived Medicines
-
May 23, 2026, 16:33Why Are We Dismantling What Powers Humanity and the Global Economy? – ASH
-
May 23, 2026, 16:24Marc Wittwer: A Practical Viscoelastic-Guided Algorithm for Trauma-Induced Coagulopathy in Clinical Workflow